Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, to...
BTIG analyst Sam Eiber maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $21 to $18.
Needham analyst Serge Belanger downgrades Evolus (NASDAQ:EOLS) from Buy to Hold and maintains the price target from $22 to $22.
